JPRN-UMIN000006811已完成2 期
Randomized phaseII study of S-1 and concurrent radiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer. (JCOG1106) - Randomized phaseII study of S-1 and concurrent radiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer. (JCOG1106)
Japan Clinical Oncology Group (JCOG)0 个研究点目标入组 100 人开始时间: 2011年12月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Interstitial pneumonia or fibroid lung 2) Watery diarrhea 3) Severe complication, such as heart disease, renal disease, and hepatic disease 4) Patients requiring the administration of flucytosine, phenytoin or warfarin potassium 5) Simultaneous or metachronous (within 5 years) double cancers, with the exception of intramucosal tumor curable with local therapy 6) Active infection requiring systemic therapy 7) Fever over 38 degrees Celsius 8) Pregnant or lactating women or women of childbearing potential and men who want to get partner pregnant 9) Psychosis 10) Patients requiring systemic steroids medication 11) Patients who can' t receive neither iodic drug nor gadolinium because of drug allergy "
研究者
相似试验
招募中
2 期
Comparing the combination of Ribociclib plus goserelin acetate with hormonal therapy versus combination chemotherapy in premenopausal or perimenopausal patients with advanced or metastatic breast cancerCTRI/2019/09/021333ovartis Healthcare Pvt Ltd
未知
2 期
A Randomized Phase II study of S-1 and LV versus S-1, LV and L-OHP versus S-1 and CDDP in Patients with Advanced Gastric CancerGastric CancerJPRN-jRCT2080221595Taiho Pharmaceutical Co., Ltd.144
招募中
2 期
Phase II study of neoadjuvant S-1 concurrent radiotherapy for borderline resectable pancreatic cancerborderline resectable pancreatic cancerJPRN-UMIN000009172JASPAC50
进行中（未招募）
不适用
Randomized phase II study of two associations of rituximab and chemotherapy, with a pet-driven strategy, in patients from 18 to 59 with DLBCL CD20+ lymphoma and 2 or 3 adverse prognostic factors of the age-adjusted IPI - LNH2007-3BCD20+ diffuse large B-cell lymphomaMedDRA version: 9.1Level: LLTClassification code 10012818Term: Diffuse large B-cell lymphomaEUCTR2007-000699-18-FRHospices Civils de Lyon222
进行中（未招募）
不适用
Randomized phase II study of two associations of rituximab and chemotherapy, with a pet-driven strategy, in patients from 18 to 59 with DLBCL CD20+ lymphoma and 2 or 3 adverse prognostic factors of the age-adjusted IPI - LNH2007-3BEUCTR2007-000699-18-BEGroupe d'Etude des Lymphomes de l'Adulte(GELA)222